Sonoma Pharmaceuticals sees promise in UTI treatment for children

BOULDER, CO - Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a developer of healthcare products, has highlighted a recent study published in the journal Neurourology and Urodynamics that discusses the potential of its product, Microdox®, in treating urinary tract infections (UTIs) in children, particularly those with bladder dysfunction. The study suggests that Microdox, a super-oxidized solution using Sonoma's patented Microcyn® technology, could be beneficial for children who need clean intermittent catheterization.

The research indicates that bladder irrigation with electrochemically activated solutions like Microdox may be a viable therapeutic option, potentially improving outcomes for these patients. Clinical trials have shown that such solutions can prevent asymptomatic bacteriuria without adverse effects, although further multi-center trials are necessary to confirm long-term preventative benefits.

Amy Trombly, CEO of Sonoma Pharmaceuticals, expressed optimism about the ongoing research into Microdox's ability to reduce UTIs in various patient groups. The company's mission is to enhance patient quality of life through its innovative Microcyn technology.

Sonoma Pharmaceuticals specializes in stabilized hypochlorous acid products for various medical applications, including wound care, dermatology, and podiatry. Its products are sold in over 55 countries, with operations in Boulder, Colorado, Guadalajara, Mexico, and Roermond, Netherlands.

Microdox is currently available in Australia and New Zealand, where it is approved for the prevention and treatment of UTIs. It is distributed through Sonoma's partner, Te Arai BioFarma Ltd., a provider of medical devices and specialty medicines in Australasia.

This news is based on a press release statement and includes forward-looking statements subject to risks and uncertainties. These cautionary details include the possibility that scientific data may not meet regulatory standards, market penetration may not be as expected, and the impact of various regulatory and marketing requirements in different countries. Sonoma Pharmaceuticals disclaims any obligation to update forward-looking statements, except as law requires.

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) has been navigating a challenging financial landscape, as indicated by the latest data from InvestingPro. With a market capitalization of just $2.47 million, the company is considered a micro-cap stock, which typically entails higher volatility and risk for investors. Despite the small size, one of the InvestingPro Tips highlights that Sonoma holds more cash than debt on its balance sheet, which can be a positive sign of financial stability in the short term. However, another tip suggests that the company is quickly burning through cash, which could present liquidity challenges if not managed effectively.

Get The App

Join the millions of people who stay on top of global financial markets with Investing.com.

Download Now

The company's recent share price performance reflects significant volatility, with a 6-month price total return of -78.91%, indicating that the stock has taken a substantial hit. Furthermore, the price is currently at just 10.39% of its 52-week high, which could suggest either a buying opportunity for value investors or a sign of ongoing distress, depending on one's investment perspective. This volatility is something potential investors should consider, especially in light of the company's focus on advancing its Microcyn® technology and expanding the use of its products like Microdox®.

For those interested in a deeper dive into the financial health and future prospects of Sonoma Pharmaceuticals, InvestingPro offers a comprehensive range of additional InvestingPro Tips, with a total of 12 tips available. These tips can provide valuable insights into the company’s profitability, stock performance, and analyst predictions. To access these insights and refine your investment strategy, consider using the coupon code PRONEWS24 for an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.